Clinical trial for OVA1 blood test showing promising results for detecting ovarian cancer

July 31, 2012 by Bob Yirka in Cancer weblog

(Medical Xpress) -- Researchers at Vermillion, a medical diagnostics company have announced that clinical trials for its OVA1® blood test diagnostic tool have shown promising results. The tool, part of Vermillion’s OVA500 program is aimed at developing tests that provide doctors and patients with better information regarding whether ovarian growth’s (tumors) are cancerous or simply benign cysts, prior to surgery.

OVA1 was first approved for back in 2009, giving a hint as to why such tests tend to cost so much once they are finally approved. Lumps or tumors in ovaries are generally first discovered by manual manipulation of the pelvis by a doctor; unfortunately, the discovery doesn’t allow them to fully understand their nature without resorting to a biopsy. A that could reveal the type of tumor would save time, money and emotional stress for patients. If approved for use by doctors, OVA1 would allow a medical professional to take a small blood sample at the time that any unusual changes in the ovary are noticed. Testing involves using software analysis of the sample using proprietary algorithms developed by Vermillion, it performs calculations on five immunoassays and produces a number that indicates the likelihood of a tumor of being malignant. In the trials, which are conducted independent of Vermillion, 494 patients were involved in the most recent trial (a thousand have participated overall) with the focus on women already diagnosed with still in the early stages and those that are premenopausal. The premenopausal group was included in the study because few women in that group get that type of cancer but a lot of them get benign cysts.

Overall it appears OVA1 did quite well, finding a sensitivity of 94% for the premenopausal patients and 91% for those who were known to have early stage cancers. The percentages indicate the ability of the blood test to detect cancer (or rule it out) in the people tested. In addition, false positives were rated as very low (just 2%).

The announcement caused shares of Vermillion stock to rise significantly, but more importantly, suggests that the blood test works as advertised which means that someday soon, women may perhaps be spared the torment of undergoing a surgical procedure and then worse perhaps, waiting two or more days for the results, when all they actually have is a benign cyst.

More information: Press release

© 2012 Medical Xpress

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Small cancer risk following CT scans in childhood and adolescence confirmed

The gap between life expectancy in patients with a mental illness and the general population has widened since 1985 and efforts to reduce this gap should focus on improving physical health, suggest researchers in a paper ...

Cancer created 12 hours ago | popularity not rated yet | comments 0

Changing cancer's environment to halt its spread

By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Novel RNA-based classification system for colorectal cancer

A novel transcriptome-based classification of colon cancer that improves the current disease stratification based on clinicopathological variables and common DNA markers is presented in a study published in PLOS Medicine this w ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Low radiation scans help identify cancer in earliest stages

A study of veterans at high risk for developing lung cancer shows that low-dose computed tomography (LDCT) can be highly effective in helping clinicians spot tiny lung nodules which, in a small number of patients, may indicate ...

Cancer created 15 hours ago | popularity not rated yet | comments 0

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Cancer created 17 hours ago | popularity not rated yet | comments 0


Study says empathy plays a key role in moral judgments

Is it permissible to harm one to save many? Those who tend to say "yes" when faced with this classic dilemma are likely to be deficient in a specific kind of empathy, according to a report published in the scientific journal ...

Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens

Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...

If you can remember it, you can remember it wrong

(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...

B vitamins could delay dementia

(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...

Insight into the dazzling impact of insulin in cells

Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.

Reducing caloric intake delays nerve cell loss

Activating an enzyme known to play a role in the anti-aging benefits of calorie restriction delays the loss of brain cells and preserves cognitive function in mice, according to a study published in the May ...